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Frailty is a syndrome characterized by the decline in the physiologic reserve and function of
several systems, leading to increased vulnerability and adverse health outcomes. While
common in the elderly, recent studies have underlined the higher prevalence of frailty in
chronic diseases, independent of age. The pathophysiological mechanisms that
contribute to frailty have not been completely understood, although significant
progresses have recently been made. In this context, chronic inflammation is likely to
play a pivotal role, both directly and indirectly through other systems, such as the
musculoskeletal, endocrine, and neurological systems. Rheumatic diseases are
characterized by chronic inflammation and accumulation of deficits during time.
Therefore, studies have recently started to explore the link between frailty and
rheumatic diseases, and in this review, we report what has been described so far.
Frailty is dynamic and potentially reversible with 8.3%–17.9% of older adults
spontaneously improving their frailty status over time. Muscle strength is likely the most
significant influencing factor which could be improved with training thus pointing at the
need to maintain physical activity. Not surprisingly, frailty is more prevalent in patients
affected by rheumatic diseases than in healthy controls, regardless of age and is
associated with high disease activity to affect the clinical outcomes, largely due to
chronic inflammation. More importantly, the treatment of the underlying condition may
prevent frailty. Scales to assess frailty in patients affected by rheumatic diseases have
been proposed, but larger casuistries are needed to validate disease-specific indexes,
which could allow more accurate prognostic estimates than demographic and disease-
related variables alone. Frail patients can be more vulnerable and more difficult to treat,
due to the risk of side effects, therefore frailty should be taken into account in clinical
decisions. Clinical trials addressing frailty could identify patients who are less likely to
tolerate potentially toxic medications and might benefit from more conservative regimens.
In conclusion, the implementation of the concept of frailty in rheumatology will allow a
better understanding of the patient global health, a finest risk stratification and a more
individualized management strategy.
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Life expectancy has markedly increased worldwide during the
last decades, mainly due to medicine progresses (1). Therefore,
the number of older adults has increased and the population of
people aged over 60 years is estimated to double within the next
30 years (2). The risk to develop a chronic disease with cognitive
and physical impairment increases with aging and is expected to
represent the next major medicine challenge. Nonetheless,
individuals may have the same chronological but very different
biological ages (3), depending on genetic, biological, and
environmental factors as well as physical, psychological, and
social determinants. In the attempt to define the more vulnerable
subjects, the concept of frailty was introduced in the 1950s and
1960s first in geriatric medicine, but only in the recent years it
gained attention by the scientific community (2). At the earlier
stages of research, the term frailty was used as a synonymous of
aging, disability, or comorbidity, since these states are often
overlapping. However, the concepts are different: advanced age
does not necessarily mean vulnerability, disability means loss of
function and comorbidity implies two or more diseases (4). As a
general rule, frailty indicates a decreased physiological reserve
and compromised capacity to maintain homeostasis as a
consequence of time-related, multiple, accumulated deficits.
A physiological decline in organ function occurs invariably
with aging but this process is aberrant in frailty to involve
multiple systems, leading to the dysregulation of the
homeostatic balance with vulnerability in response to minor
stressor events. This brings to further reserve decrease, in a
vicious cycle (5, 6). Possible etiologic factors include genetic and
epigenetic mechanisms (7, 8), metabolic and environmental
stressors and acute or chronic diseases (9). As a consequence,
multiple processes are altered, with the major role of the
immune, musculoskeletal, endocrine, and neurological systems.Frontiers in Immunology | www.frontiersin.org 2Frailty is due to the impaired function of these inter-related
physiological systems, lowering their reserve under the threshold
needed to compensate changes (6).
Despite a standard definition of frailty remains lacking, the
most inclusive is the one provided by the WHO: i.e. a clinically
recognizable state in which the ability to cope with everyday or
acute stressors is compromised by an increased vulnerability
brought by age-associated decline in physiological reserve and
function across multiple organ systems (2).
Frail adults are at increased risk of death and negative health
outcomes, including falls, fractures, disability, cognitive decline
and poor quality of life, with an impact on medical costs and
health care resources (10). The prevalence of frailty in the general
population aged 65 years and older can range between 4% and
59%, depending on the criteria used and about 25% of people
aged 80 years or older are considered to be frail (11). Of note, a
high prevalence of frailty has also been found in selected
populations with specific diseases or chronic conditions, not
necessarily associated with age, such as cirrhosis (12), HIV
infection (13), end-stage renal disease (14) and heart failure
(15). Nonetheless, frailty is not invariably age-related, as chronic
conditions can cause vulnerability and increase the risk of
negative outcomes. Rheumatic diseases affect subjects at any
age and the chronic condition might reduce the physiological
reserve and increase vulnerability. In this field, studies on frailty
are limited and the implementation of this concept could provide
further information on the overall health status of patients.FRAILTY MEASUREMENT
Several frailty measurements have been created for clinical and
research purposes (16, 17). Table 1 illustrates the most widely
used tools (26), with Fried’s frailty phenotype and the frailtyTABLE 1 | Comparison of different frailty scales.
Index Country of
origin






Fried’s Frailty Phenotype USA 5 Frailty ≥3; pre-frail 1–2; Robust=0 <10 yes (18)
FI-CD Canada 30+ Continuous score; frailty cut-off >0.25 ≈30 no (19)
Gill Frailty Measure USA 2 Moderately frail if rapid gait>10 s or could not
stand from the chair.
Severely frail if meet both criteria.
<10 no (20)
Frailty/Vigor Assessment USA 13 Score:
0–9 frail attributes. 0–4 vigorous attributes
Frail: ≤1 vigorous and ≥4 frail attributes.
Vigorous: ≥3 vigorous and ≤2 frail attributes.
Transitional: neither frail nor vigorous.
<20 no (21)
CSHA-CFS Canada 7 Moderately frail: 6
Severely frail: 7
<20 no (22)
Brief Frailty Instrument Canada 5 Index score range 0–5 (high score=high risk):
4 categories:
0; 1; 2; ≥3
<20 no (23)
Vulnerable Elders Survey Japan 13 Frail if score ≥3 <15 no (24)
FRAIL USA 5 Frailty ≥3; pre-frail 1–2; Robust=0 <10 no (25)October 2020 | Volume 11 | Article 57FI-CD, Frailty Index of Accumulated Deficits; CSHA-CFS, Canadian Study of Health and Aging Clinical Frailty Scale; FRAIL, Fatigue, Resistance, Ambulation, Illness and Loss of
Weight Index.6134
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employed. The Fried’s frailty phenotype is also known as the
Cardiovascular Health Study (CHS) Index, from the study that
originally used it (18) and includes physical features, or
“phenotype,” defining frailty as the presence of three or more
of the following: (i) weight loss: body mass index (BMI) ≤18.5 or
self-reported unintentional weight loss ≥4.5 kg in the previous
year; (ii) exhaustion: self-reported; (iii) slowness: walking 4 m in
6.13 sec or more for height ≤159 cm or in 5.25 s or more for
height >159 cm; (iv) weakness: grip strength (measured with a
dynamometer) ≤17 kg for BMI ≤23 kg/m2, ≤17.3 kg for BMI 23.1
to 26 kg/m2, ≤18 kg for BMI 26.1-29 kg/m2, or ≤21 kg for BMI
>29 kg/m2; (v) low physical activity: measured with the
International Physical Activity Questionnaire (27). Subjects are
considered as “pre-frail” when only one or two criteria are met,
whereas subjects are considered as not frail or robust in the
absence of any of the aforementioned factors. The Fried index is
predictive of adverse clinical outcomes, including mortality (28,
29). However, its widespread clinical application is limited by the
inclusion of measurements not routinely used in clinical practice
and the exclusion of psychosocial components or cognitive
impairment. Nonetheless, the Fried’s frailty phenotype has
been widely applied and validated (30–32).
As problems accumulate over time, less or more rapidly,
frailty might be seen as the sum of deficits, leading to increased
vulnerability. The Frailty Index (FI) of Cumulative Deficits (FI-
CD) was developed by Rockwood, Molginer and Mitnitski (19)
as part of a 5-year prospective cohort study (n=10263) conducted
in elderly people in Canada (mean age 82 years). Ninety-two
baseline variables of symptoms (eg, low mood), signs (based on
physical exam), abnormal laboratory values, disease states and
deficits were considered and the presence or absence of each
variable is set as proportion of the total (eg, 15 deficits present
out of 92 variables gives a frailty index of 15/92=0.16). It has been
shown that the list of variables can be reduced to 30, without
missing predictive validity (33). The exact list for inclusion in the
FI-CD does not specifically matter. In fact, a process for creating
a cumulative deficits frailty index has been defined (34) and
variables can be selected if they meet the following criteria: (i)
associated with health status, (ii) prevalence increasing with age;
(iii) not saturated too early, (iv) reflective of a range of
physiological systems, (v) if it is to be used serially on the
same people, the items need to be the same. On the contrary,
when considering frailty of different groups of people, different
indexes can be compared, as although items may differ, results
are similar.
The FI-CD has a high predictive value for adverse clinical
outcomes (35) and it seems that its total score, rather than type of
health deficit, may better predict adverse outcomes (36). An
upper limit is believed to be set at 0.67, beyond which the
likelihood of survival is minimal (37). The FI-CD has also
been applied to the Survey of Health, Ageing and Retirement
(SHARE) study in Europe, where it is termed the SHARE-FI
(38). This continuous FI allows greater ability to discriminate
between different degrees of frailty, compared to the Fried
phenotype (39). The main limitation is the time-consumingFrontiers in Immunology | www.frontiersin.org 3process to calculate the index. Nonetheless, this two frailty
scales show significant overlapping in their identification of
frailty and in the ability to predict disability and mortality (40).INFLAMMATION AND FRAILTY
The etiology of frailty remains poorly understood but it is likely
that numerous factors are involved in the pathogenesis and more
systems are affected, leading to the loss of homeostasis and to a
vicious cycle with further decrease of the physiological reserve.
The genetic background that can influence frailty has been
studied, and genes found to be associated with frailty are
related to inflammation, muscle function, glucose and lipid
metabolism, hypothalamic-pituitary-adrenal axis function,
apoptosis, and homeostasis, such as genes encoding for
methionine synthase, fibronectin or transcriptional factors
(41). Although genetics seems to have an impact on frailty,
acquired and environmental factors probably have the highest
contribution, also through epigenetic modifications (42). On
these bases, a multi-systemic dysregulation occurs and multiple
biologic mechanisms are altered.
The immune system has a key role in this context and patients
affected by rheumatic diseases might thus have an additional risk
factor for frailty. It has been shown that chronic inflammation
contributes to the development of frailty, both directly and
indirectly through other processes. A direct association between
frailty and increased total white blood cell count has been found
(43, 44). Moreover, frailty is associated with a pro-inflammatory
T-lymphocyte phenotype, as an increased count of cluster of
differentiation (CD)8+/CD28− T cells and C-C chemokine
receptor type 5 (CCR5)+ T cells has been demonstrated (45, 46).
The analysis of monocytes gene expression has further shown the
upregulation of several stress-responsive inflammatory pathway
genes in frail individuals (47), while several pro-inflammatory
molecules are associated with frailty. Elevated serum
concentration of interleukin (IL)-6 was observed in frail elderlies
(43, 48, 49), and higher IL-6 levels were produced by peripheral
blood cells (PBMCs) from frail subjects when stimulated by
lipopolysaccharide (LPS), compared with non-frail adults LPS-
stimulated PBMCs (50). In IL-10 deficient mice with features
mimicking human frailty, such as muscle weakness, IL-6 was
significantly higher compared to age- and gender-matched
C57BL/6J control mice (51). C-reactive protein (CRP), tumor
necrosis factor-a and CXC chemokine ligand-10, a potent pro-
inflammatory mediator, are also elevated in frail older adults (47,
49, 52). Elevated levels of neopterin, a marker for immune
activation mediated by monocytes and macrophages, are
associated with frailty in community-dwelling older adults
independently of IL-6 levels, suggesting that immune activation
plays a key role in the pathogenesis of frailty. The underlying factor
that stimulates the immune system activation can be an
autoimmune process, as happens in rheumatic diseases, or a
malignancy, or a persistent infection (53). In fact, positive anti-
CMV immunoglobulin G titers have been found to be associated
with frailty (54, 55).October 2020 | Volume 11 | Article 576134
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function adequately in the quiescent state but fails to respond
appropriately to a stressor event. Evidence suggests that in frailty
an abnormal, low-grade inflammatory response persists for a
long period after removal of the initial inflammatory stimulus
and is hyper-responsive to further stimuli. In fact, acute episodes
of illness or exacerbation of chronic conditions may accelerate
the development of frailty or worsen its clinical presentation and
adverse outcomes (5).
The changes associated with frailty largely overlap with aging,
where a chronic, sterile, systemic, low grade inflammation, also
referred to as “inflammaging,” occurs and leads to increased levels
of pro-inflammatory mediators (although within the normal
ranges) compared to younger individuals. Genetic, epigenetic and
environmental factors contribute to this phenomenon. Senescent
immune cells can acquire a proinflammatory phenotype, misplaced
nucleic acids can accumulate and trigger an immune response, self-
reactive T-cells can be released, infections or gut disbyosis can
promote andmodulate the inflammatory status. During life, chronic
diseases, physical activity, stressors, infections and nutrition may
play a role in this process, contributing to the development of
different phenotypes. Inflammaging can be considered the
consequence of an altered immune function with a dysregulated
immune response, similarly to the frail syndrome and although
evidence is scarce, it would be intriguing to conceive frailty as an
inflammaging-related disease (56) (Figure 1). In this regard, the
cellular and molecular mechanisms that guide homeostatic frailtyFrontiers in Immunology | www.frontiersin.org 4are currently poorly characterized. In response to a variety of
stresses (trauma, infection, cancer) tissues operate the healing
process by chronologically overlapping phases of acute
inflammation, resolution of inflammation, proliferation and
remodeling, during which macrophages play a crucial role (57,
58). Macrophages operate such functions by exploiting different
activation programs, switching their phenotype from an M1-
(classically activated macrophages) to an M2- (alternatively
activated macrophages) polarized activation. While M1-polarized
macrophages are essential to initiate the inflammatory response
after injury, by releasing several inflammatory mediators (e.g. IL-6,
tumor necrosis factor (TNF)-a, IL-1, and nitric oxide), late
switching to an M2 phenotype provides anti-inflammatory
cytokines (e.g., transforming growth factor (TGF)-b and IL-10),
phagocytosis of apoptotic neutrophils and removal of damaged
cells, hence promoting resolution of inflammation and restoration
of tissue homeostasis. Perturbation of this dynamic reprogramming
of macrophage functions may lead to a failure of resolution of
inflammation, eventually resulting in the formation of dysfunctional
fibrotic tissue (59). Molecular determinants that affect the
macrophage M1 and M2 polarization balance include members of
the peroxisome proliferator-activated receptor (PPAR), Krüppel-
like factor (KLF), IFN-regulatory factors (IRF), signal transduction
and activator of transcription (STAT), nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-kB), and hypoxia-inducible
factor (HIF) families (60). In particular, whereas NF-kB activation
occurs temporarily during a normal immune response, it isFIGURE 1 | Pathogenetic pathways leading to inflammaging and frailty. With aging, environmental factors can lead to epigenetic modifications, dysregulation of
several genes and can promote a pro-inflammatory phenotype of senescent immune cells. On the other hand, rheumatic diseases can develop on a predisposed
genetic background, triggered by environmental factors. Chronic inflammation can lead to epigenetic modifications, dysregulation of gene transcription and persistent
pro-inflammatory phenotype of immune cells. In both situations, in response to stressor events, the immune system is inappropriately hyperactivated and the ability
to promptly restore homeostasis is compromised. PPAR, peroxisome proliferator-activated receptor; FLF, Krüppel-like factor; IRF, interferon-regulatory factor; STAT,
signal transduction and activator of transcription; NF-kB, nuclear factor kappa-light-chain-enhancer of activated B cells. HIF, hypoxia-inducible factor families; NAD,
nicotinamide adenine dinucleotide; NAMPT, Nicotinamide phosphoribosyltransferase; SIRT1, sirtuin 1; WBC, white blood cells.October 2020 | Volume 11 | Article 576134
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such as rheumatoid arthritis, systemic lupus erythematosus, type 1
diabetes, multiple sclerosis, inflammatory bowel disease (61).
Further, accumulation of the p50 NF-kB subunit results in the
formation of the transcriptionally inactive p50 NF-kB homodimer,
a key regulator of M2-driven inflammatory reactions and inhibitor
of M1 macrophage polarization controlling the resolution of the
inflammatory response. Accordingly, p50-deficient mice display
exacerbated M1-driven inflammation and homeostatic
dysregulation (62). In agreement, lack of p50 NF-kB in self-
antigen-pulsed unstimulated dendritic cells results in activation of
CD8(+) T lymphocytes and induction of autoimmunity (63). More
recently the homeostatic role of myeloid-specific p50 NF-kB was
strengthen by the observation that its accumulation promotes
expansion of myeloid-derived suppressor cells (MDSC) (64), a
subtype of myeloid cell primarily beneficial upon restoring
homeostasis after inflammation (65). In addition, epigenetic
modifications with involvement of miRNAs, histone methylation
and acetylation have emerged as regulators of inflammation (66–
68). In this regard, reduction of Nicotinamide Adenine Dinucleotide
(NAD) levels, as a consequence of the age-dependent decline of the
enzyme Nicotinamide phosphoribosyltransferase (NAMPT),
represents a major driver of frailty in the elderly (69, 70). This
event threatens redox reactions orchestrated by NAD+ (71), as well
as the NAD-dependent activity of the deacetylase SIRT1, a major
regulator of gene transcription acting through modification of
chromatin-associated proteins (72), suggesting that age-related
loss of NAMPT/NAD+/SIRT1 activity is likely to undermine the
efficiency of antioxidant, metabolic and anti-inflammatory
pathways (73, 74).
Interestingly, while the efficiency of the NAMPT/NAD+/
SIRT1 system is controlled by a balanced nutritional supply of
tryptophan and vitamin B3, which provides the primary and the
rescue pathways for the synthesis of NAD, respectively (75),
accumulation of p50 NF-kB is promoted by long exposure to
bacterial-derived products, including LSP, suggesting that its
dysregulation may alter the delicate balance between immune
response and immune tolerance in sites exposed to pathogenic
microorganism and commensal flora, such as the intestinal
tract (76).
Remarkably, the definition of myeloid cell plasticity in
pathology has been recently reformulated by the concept of
trained immunity, including a set of epigenetic and metabolic
events promoting the functional reprogramming of the myeloid
cells and myeloid progenitors, in response to secondary
stimulation with pathogens, Toll-like receptor agonists and
cytokines (77). According to this concept, innate immune cells
retain a “memory” of previous microbial and/or traumatic
encounters, which influences subsequent immune responses to
reproduce similar patterns of activation and inhibition,
potentially compromising the ability to promptly activate
homeostatic mechanisms.
Therefore, the life events and the environment can lead to the
alteration of the efficiency of homeostatic systems, which may
likely predispose to a status of “homeostatic frailty” linked to
inflammatory, autoimmune and metabolic disorders.Frontiers in Immunology | www.frontiersin.org 5TISSUE CHANGES AND FRAILTY
Inflammation may contribute to frailty directly or indirectly
through its detrimental effects on other organ systems
(Figure 2), for example leading to muscle mass decrease, loss
of strength, reduced physical activity, anemia, clinical and
cardiovascular diseases and poor nutrition (78–82). The
musculoskeletal system plays a key role in frailty, as sarcopenia
mostly related to physical inactivity leads to disability, weakness
and slowed motor performance. Sarcopenia is the decline in
skeletal muscle mass with decreased strength or function. It is
caused by age-related alterations of motor neurons and muscle
fibers, poor nutrition and physical activity, endocrine changes or
chronic inflammation (83, 84).
The endocrine system is also involved in frailty, particularly
the hypothalamic–pituitary–adrenal axis (85). Sex hormones,
glucocorticoids, growth hormone (GH) and insulin growth
factor-1 (IGF-1) are critical for muscle metabolism and
trophism. In fact, androgens and, to a lesser extent, estrogens,
activate the downstream signaling with transcription of muscle
proteins, reduction of protein degradation and myocyte
proliferation, either directly or indirectly through increasing
the expression of IGF-1 receptors on muscle cells .
Glucocorticoid hormone has a catabolic effects on muscle,
activating the degradation of ubiquitin-conjugated proteins.
GH is the main promoter of body growth in children and
exerts anabolic effects in adults, including effects on myocytes,
increasing protein synthesis, inhibiting protein degradation and
inducing gluconeogenesis. IGF-1, produced in the liver in
response to circulating GH, is the main mediator of these
effects. Vitamin D is another factor involved in skeletal muscle
trophism and lower levels were associated with lower muscle
strength, poor muscle function and increased muscle loss (86).
A delicate balance of these hormonal factors determines
muscle trophism and strength.
The age-related decrease of estrogen in women and testosterone
in older men leads to decline in muscle mass and muscle strength.
Circulating levels of the precursor of sex hormones
dehydroepiandrosterone sulfate (87) and of IGF-1 (88) are
significantly lower in frail older adults. Glucocorticoids induce
muscle atrophy by promoting myofibrillar degradation and
inhibiting protein synthesis. Higher levels of evening cortisol, 24-
hour mean cortisol, and blunted diurnal variation of cortisol have
also been associated with the frailty syndrome in the elderly (89).
Glucocorticoid therapy is also independently associated with
vitamin D deficiency, since steroids interfere with vitamin D
metabolism, due to increased renal transcription and expression
of vitamin D-24-hydroxylase, which degrades active metabolites
such as 25(OH)D and 1,25(OH)D (90). Vitamin D insufficiency is
associated with frailty, particularly in older men (91). Vitamin D is a
well-known central regulator of bone homeostasis, by determining
calcium-phosphorus balance. In addition, vitamin D exerts several
extra-skeletal effects, which include muscle tissue trophism,
improvement of glucose and fatty acid metabolism and
modulation of the immune system, with low levels associated
with autoimmune diseases pathogenesis (92). In fact, vitamin DOctober 2020 | Volume 11 | Article 576134
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macrophages recruitment, inhibiting pro-inflammatory cytokines/
chemokines expression and enhancing tolerogenicity of dendritic
cells (93), thus playing an immunomodulatory role andmaintaining
immune homeostasis. Not only almost all the immune cells present
vitamin D receptor and can be modulated by this hormone, but are
also local producers of vitamin D under specific signals (94).
Therefore, a deficiency of this hormone may trigger or exacerbate
chronic low-grade inflammation, thus enhancing the process that
leads to frailty.
The neurological system undergoes structural and functional
changes with aging, involving both neurons and microglial cells.
Microglial cells can be activated by injury and inflammation,
resulting in an hyperresponsive phenotype causing neural damage
in response to small stimuli. Frail elderlies have an increased risk of
developing dementia or cognitive impairment in the long-term
period, with a faster decline associated with increasing frailty. They
have also higher risk of developing delirium, and frail patients with
delirium have a significant reduced survival compared to non-frail
subjects with delirium (5, 95–97). Moreover, frailty is also associated
with depression. A meta-analysis showed that each condition is
associated with an increased incidence and prevalence of the other,
and can be a risk factor for the development of the other (98). Frailty
negatively impacts the course of depression (99) and the co-
existance of the two conditions is associated with higher
mortality (100).
Despite the increasing evidence regarding the multifactorial
etiology of frailty, further clinical and mechanistic studies areFrontiers in Immunology | www.frontiersin.org 6needed to better understand the complex pathophysiology of
this syndrome.FRAILTY IN RHEUMATIC DISEASES
Most recently, frailty has moved past being exclusively sought in
the geriatric population, and research on this concept has grown
in many clinical areas, possibly because of global aging, and
recognizing a patient as frail might give a clinical advantage and
better guide the management.
In rheumatology, limited data are available and agree on
underlining that frailty should constitute a clinimetric assessment
and a prognostic factor. This is well represented by both non
inflammatory conditions such as osteoarthritis and osteoporosis,
and autoimmune diseases such as rheumatoid arthritis, systemic
lupus erythematosus, systemic sclerosis, and ANCA-associated
vasculitis. In rheumatic diseases, the processes leading to frailty
may be related to the disease itself or to the treatment with
glucocorticoids and/or with disease-modifying antirheumatic
drugs (DMARDs) used in the management of the chronic
condition, which may have a dual impact on frailty, on the one
hand beneficial on disease activity, on the other hand detrimental,
due to side effects, as discussed in each section.
Osteoarthritis
Osteoarthritis (OA) is a chronic and disabling condition whose
prevalence increases with age. Around 20% of middle-aged andFIGURE 2 | The proposed pathogenetic pathways leading to frailty development include genetic and environmental factors, largely mediated by chronic
inflammation, and lead to adverse outcomes.October 2020 | Volume 11 | Article 576134
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presents radiographic signs of OA. As knee OA can lead to
disability, a proportion of these patients undergoes joint
replacement, which has a mortality risk up to 10% (101). As
OA is more prevalent in the elderly, frailty often coexists and the
association between the two conditions is significant in both
directions. Most relevant to the rheumatologist, frailty predicts
mortality in subjects with OA (102). Therefore, it can be
considered a new prognostic factor to stratify the population
with OA and implement their management.
Several studies have examined the relationship between frailty
and OA, all suggesting that the frailty state should be assessed when
considering treatment of OA, as it may be essential in targeting
therapeutic interventions. Table 2 illustrates the more recent studies
of the prevalence of frailty in patients with OA, while studies on the
prevalence of OA in frail subjects remain undetected. Despite
measuring frailty with different methods and considering OA at
different sites, all these studies found a high prevalence of frailty in
OA patients, with crude rates ranging from 24% to 60% (103–108).
Frailty can occur in patients with OA for several reasons.
Patients with lower extremity OA, especially hip and knee OA,
are likely to reduce their physical activity, which results in loss of
muscle mass and increased incidence of falls than age-matched
healthy controls (110). OA-related pain also plays a role, as it has
been associated with an increased risk of developing frailty
compared to people with OA and no pain (103, 107). Pain is
directly linked to a loss of physical function and is often
associated with cognitive impairment, both of which are
observed in frail patients (111). The potential underlying
pathways linking OA and frailty are not well understood and
studies are scarce. A possible mechanism involves inflammation.
Chronic, low grade inflammation occurs in OA and pro-
inflammatory markers, as IL-6 and CRP, have been detected in
blood of individuals with OA (112, 113). This mild inflammation
can induce sarcopenia and decreased physical activity (109).
Intraarticular glucocorticoid injections can be used in hip and
knee OAmanagement (114) and are especially useful in reducing
pain (115). However, although presenting minimal systemic
exposure and toxicity, they can contribute to cartilage loss, and
efficacy has been demonstrated only in the short-term. Physical
and psychosocial approaches are preferred, at least at early
stages, analgesics can be used, while DMARDs are not
recommended (114).Frontiers in Immunology | www.frontiersin.org 7Further research is required to understand the patho-
physiological pathways and identify potential targets to prevent
the development of frailty in OA patients.
On the other hand, frailty might be a risk factor for the
development of OA. In frail patients sarcopenia is frequently
observed and this can lead to joint instability and increase the
likelihood of biomechanical injury. Moreover, frail subjects have
a higher risk of falls (18), which could result in fractures,
disabi l i ty and development of post-traumatic OA.
Furthermore, higher circulating levels of pro-inflammatory
cytokines, such as IL-6, CRP, and TNF-a, are present in frail
subjects (43, 49, 116) and a possible accumulation of these
mediators in joints has been hypothesized, inducing local low-
grade inflammation, cartilage destruction and leading to an
altered catabolism of joint structures (109). Older individuals
usually have changes in joint cellular composition and on this
substrate a pro-inflammatory state might impair the ability of
joint repair, with the development of OA. Frailty may therefore
be considered as an additional risk factor for the development of
OA (109). Of note, in a European multicenter study, Castell and
colleagues found a risk of frailty (defined according to Fried’s
criteria) from 1.5 to nearly 3-fold higher in patients with OA in
any joints, with hip OA associated with a greater risk of frailty
compared to knee OA, perhaps due to major disability associated
with hip OA and, if multiple joints were involved, the risk was 8-
fold higher (105). OA is associated with greater incidence of
frailty (104) and with accelerated frailty progression if frailty is
already present (103).
Osteoporosis
Osteoporosis is characterized by reduced bone mass and structural
deterioration of bone tissue, resulting in increased bone fragility
and higher risk of fractures. The risk of fragility fractures increases
with age and in presence of other risk factors, such as treatment
with glucocorticoids or diagnosis of rheumatoid arthritis. A
history of previous fractures affects the prognosis, with up to
30% one-year mortality for hip fractures (117, 118).
Cook and colleagues reported an association between higher
frailty index and lower bone density, assessed by calcaneal
quantitative ultrasound in a cohort of more than three
thousand men aged 40 to 79 years, after adjusting for age.
Possible explanations are related to reduced mechanical
loading resulting from sarcopenia, insufficient physical activity,TABLE 2 | Studies on frailty in osteoarthritis (OA),.
Type of OA Gender Measurement of frailty Results Ref.
Hip Male CHS Prevalence of frail patients: 8%; intermediate: 42%.
OA or hip replacement: 1.27 times more likely to be frail.
(103)
Knee Male and female SOF Prevalence of frailty: 60%.
Severity correlated with prevalence.
(104)
Hand, hip and/or knee Male and female CHS Prevalence of frailty 30% (OA any site):.
Odds higher if hip or multiple sites affected.
(105)
Knee Male and female CHS Knee pain associated with increased risk of frailty. (106)
Hand, hip and/or knee Male and female CHS OA pain associated with higher incidence of frailty (higher risk in women). (107)
Hip or knee Male and female GFI Prevalence of frailty: 24% for knee OA, 33% for hip OA. (108)October 2020 | Volume 11 | Article 5CHS Cardiovascular Health Study Index; SOF, Study of Osteoporotic Fracture index; GFI, Groningen Frailty Indicator.
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nutritional deficiencies (119).
In a meta-analysis including almost 100.000 senior men and
women from the general population, frailty was associated with a
70% increased risk for a fracture of any type (120). Moreover, the
frailty index was higher in women who reported a previous fracture
and its changes in 1 and 2 years were significantly greater in women
who had suffered a major osteoporotic fracture compared to
unfractured subjects (121). As a result, some authors suggest to
consider as frail the elderly with osteoporosis-related fractures (122).
In addition, as bone density directly correlates with the risk of
fracture (123), which is associated with worsening of frailty, we can
speculate that dual-energy X-ray absorptiometry (DEXA) may
provide information on the potential imminent risk of fracture
and, consequently, of frailty. Moreover, as osteoporosis and frailty
share etiopathogenic factors such as sarcopenia and inflammatory,
hormonal and nutritional alterations, including vitamin D
metabolism impairment (5, 124), DEXA could early identify pre-
frail or frail subjects. DEXA could also assist the clinician in the
decision for the best management for frailty. In fact, when low bone
density is detected, an investigation and correction of reversible
causes (nutritional, hormonal or inflammatory) is recommended
(125) and may also improve frailty risk. Therefore, not only the
concept of frailty needs to be implemented in patients with
osteoporosis in order improve their management (126), but also
considering DEXA in the evaluation of subjects at risk for frailty and
treating osteoporosis may be useful in the prevention and
management of frailty.
Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease which
primarily affects the joints with a polyarticular and symmetric
arthritis, but it can have extra-articular manifestations such as
constitutional symptoms and lung, skin, eye or heart involvement.
The clinical management combines the measure of disease activity
with composite indexes, a treat-to-target strategy and the use of
conventional, biological and targeted synthetic DMARDs (127–
129). The use of glucocorticoids, which can predispose to frailty, is
recommended only in the short-term, in order to rapidly reduce
inflammation, and tapering is recommended as rapidly as clinically
feasible, aiming at discontinuation within few months. Otherwise,
the dosage should be kept to a minimum, and the reasons for
continuing corticosteroid therapy should be periodically checked, in
line with patient’s risk-benefit ratio (130). The impact of chronic
steroid therapy may be detrimental on bone (131) and muscle (132)
and therefore can lead to frailty, but focused research is difficult to
perform and is currently lacking. From the few studies available on
frailty and RA, described below, disease activity seems the main
factor involved in the development of frailty. In this perspective,
glucocorticoids may be beneficial when maintained for a better
disease control. DMARDs, both synthetic and biological, are
essential for steroid sparing and have to be introduced early after
diagnosis of RA (130). However, immunosuppression can increase
the patient’s risk of infection (133), which can lead to hospitalization
and further risk of frailty. Life expectancy of patients with RA is
reduced, with a twofold increase in mortality and a decreased
lifespan of 7 to 10 years (134). Despite the progresses made inFrontiers in Immunology | www.frontiersin.org 8therapy andmanagement of RA over the last decades, mortality rate
seems to remain higher compared to general population (135),
although an improvement in 5-year mortality has been
demonstrated from the introduction of biologic DMARDs into
clinical practice (136).
RA may present with features of frailty, such as sarcopenia
(137), fatigue (138) and low physical activity, especially when the
disease is not well controlled (139). Frailty in patients affected by
RA has been evaluated in recent studies. In 2019 a cohort of 210
patients with RA was compared to a healthy control population
and, according to SHARE-FI criteria, frailty was more common
in the RA population (16.6% vs 8% among controls). Age,
comorbidities and disease activity were independently
associated with frailty (140). In a cohort of 100 patients
younger than 65 years with RA, the prevalence was 15% for
frailty and 30% for pre-frailty measured with the SHARE-FI
score. Unemployment, higher pain intensity, longer disease
duration and higher disease activity were associated with a
higher frailty score (141). Frailty appears to be related to
disease activity also in an analysis by Tada and colleagues,
where the prevalence of frail, pre-frail and normal subjects
were 18.9%, 38.9% and 42.2%, respectively. In the subgroup of
patients in remission (i.e. with a disease activity score 28 lower
than 2.6) 6.7% had frailty, while in those with moderate and high
disease activity (disease activity score 28 >3.2) 46.7% were
frail (142).
In a cohort of 124 RA cases, baseline frailty defined with the
Fried phenotype model predicted significant worsening in physical
function assessed with Health Assessment Questionnaire, even
when controlling for the effects of disease severity, disease
duration, and medication use. The trends were unchanged when
the analyses were limited to participants younger than 65 years,
suggesting that age is not the only factor involved (143). Salaffi and
colleagues recently developed and preliminary validated a
cumulative frailty index for RA patients, evaluating nutritional
status, weakness, falls, comorbidity, polypharmacy, social activity,
pain, fatigue, physical function and depression. Advanced age and
high disease activity were significantly associated with frailty, while
gender, educational level, disease duration and radiographic
damage were not related to frailty in the cohort analyzed
(144, 145).
Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune
disease that can affect any organ, with clinical manifestations
ranging from mild skin lesions to life-threatening renal,
hematological or neurological involvement (146, 147).
Management consists of a combined therapy with
glucocorticoids and immunosuppressive drugs (148). Severe
manifestations usually require high-dose glucocorticoids, with
a potentially greater impact on the development of frailty.
Moreover, as SLE affects fertile women, glucocorticoids are
introduced early in life, with greater risk of long-term
complications. Immunosuppressive drugs usually allow steroid
tapering, but some of them are burdened with severe side effects,
as cyclophosphamide which can induce ovarian failure (148),
increasing the risk of frailty development. The survival rate inOctober 2020 | Volume 11 | Article 576134
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remained stable at over 3 times higher than that of the general
population (149). In 2016 Katz and colleagues (150) assessed
frailty in a population of 152 women with SLE (mean age 48
years) using the Fried’s phenotype criteria and 20% of the sample
was classified as frail, 50% as pre-frail. Exhaustion, weakness and
inactivity were the variables most commonly present (45%, 31%
and 29%, respectively). There were no differences in age, race,
education, duration of the disease, or smoking history by frailty
classification. Steroid use was more common among pre-frail
and frail women. There was a significant worsening in ratings of
disease activity, damage and pain as frailty state moved from
robust, to pre-frail, to frail. Frail women had significantly worse
physical functioning and were more likely to have cognitive
impairment compared to both robust and pre-frail women.
Although mortality was a rare outcome, frailty was linked to a
higher risk of death, estimated around six times higher than in
robust women.
In 2019 Legge and colleagues described a frailty index for SLE,
using data from the Systemic Lupus International Collaborating
Clinics (SLICC) inception cohort (151) in 1682 SLE cases (89%
females, mean age 35.7 years, mean disease duration 18.8
months) (152) and reported that higher baseline SLICC frailty
index values were associated with increased mortality risk, even
after adjusting for age, sex, steroid use, ethnicity and baseline
disease activity. Therefore the SLICC frailty index might help to
explain the heterogeneous health outcomes in patients with SLE
and can be a useful tool to provide prognostic information and to
predict future mortality risk.
Systemic Sclerosis
Systemic sclerosis (SSc) is an immune-mediated disease
characterized by cutaneous thickening, progressive fibrosis of
skin and internal organs and vasculopathy, leading to the highest
mortality in rheumatic diseases, estimated to be four-fold higher
than general population (153, 154). Management aims at
reducing or stabilizing disease manifestations. Vasodilators are
used for vascular-related complications, immunosuppressive
therapy for inflammatory manifestations and interstitial
lung disease, while glucocorticoids have to be avoided or used
at low dosage, due to the risk of scleroderma renal crisis (155,
156). Therefore, in SSc patients, if vasodilators only are used,
therapy does not have a great impact on frailty, while if
immunosuppressive drugs need to be introduced, side effects
(157) can worsen the condition of patients affected by a
debilitating disease.
A cumulative frailty index has also been developed in
systemic sclerosis, according to the procedure described by
Searle and colleagues (34). In this study, 44 items were selected
from the Canadian Scleroderma Research Group (CSRG)
Registry as health deficits. The frailty index was applied to a
population of 1372 CSRG patients. The score was higher in
diffuse rather than limited disease, correlated with the Rodnan
Skin Score and with the damage assessed by physicians. It
increased with age, but not linearly, reflecting the fact that
patients with SSc may be vulnerable even at younger age andFrontiers in Immunology | www.frontiersin.org 9that frailty, damage assessed by physicians and age were
predictive of mortality. Irrespective of age, disease type, or time
since diagnosis, the risk of death was higher with higher frailty
index scores (158).
Frailty in SSc has also been studied in relation to interstitial
lung disease (ILD) (159). Measured using a 42-item index, frailty
was found to have a prevalence of 55% in patients with SSc-ILD
and to be strongly associated with dyspnea. The frailty index did
not significantly differ from that in a control population with ILD
not associated to a connective tissue disease, even though SSc
patients had a significantly younger age, indicating that
chronological age significantly underestimates biological age in
SSc patients and that the concept of frailty could allow a more
accurate prognostic evaluation than demographic and disease-
specific parameters alone.
ANCA-Associated Vasculitis
ANCA-associated vasculitis (AAV) includes different forms of
necrotizing vasculitis affecting predominantly the small vessels,
which have in common the serum positivity for antineutrophil
cytoplasmic antibodies (ANCA), the frequent lung involvement
and a pauci-immune crescentic glomerulonephritis, which
potentially leads to end-stage renal disease. The prevalence of
AAV is estimated around 100 per million people. The 5-year
survival rates range from 45 to 97% (160).
Severe cases involving lung or kidney are treated with high-
dose glucocorticoids and immunosuppressive drugs, either
cyclophosphamide or rituximab, for remission induction. The
maintenance regimens consist of low-dose glucocorticoids and
chronic immunosuppressive drugs (161). On the one hand this
management reduces chronic inflammation and allows good
outcomes and survival (162), on the other hand it can lead to
sarcopenia, bone loss, higher risk of infection (163) and frailty
development in the long-term.
McGovern and colleagues described a population of 83
patients aged 65 or over with a diagnosis of AAV, studying the
risk factors for mortality (164). They used the Canadian Study on
Health and Ageing Clinical Frailty Scale (22) to measure frailty.
Age, very high CRP values and baseline frailty score were
independently associated with mortality. For each additional
point on the frailty score, the risk of death approximately
doubled, even when adjusting for age, sex, ANCA status, renal
function and CRP values. Patients with a lower vs higher baseline
frailty score (≤3 vs ≥4) had no differences in time to remission or
time to relapse, but in the frailer group a greater proportion of
patients had adverse events, longer in-hospital stay and mortality
was significantly higher, with a five-year survival of 47% vs
90% respectively.NATURAL HISTORY AND MANAGEMENT
OF FRAILTY
Although the prevalence of frailty gradually increases with age (11),
it has been demonstrated that older people may have dynamicOctober 2020 | Volume 11 | Article 576134
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pre-frail and frail patients improving to a robust state (165).
Therefore, frailty is not a static state, some deficits can be reversed
and an early intervention is preferable. In longitudinal population-
based studies a range of 8.3%–17.9% of older adults spontaneously
improved their frailty state in the follow up years (166–168). Poor
prognostic factors for improvement were older age, poor handgrip
strength, weight loss, poor physical activity, hospitalizations,
previous cancer or stroke, lung disease, lower cognitive function,
diabetes, osteoarthritis, low albumin levels and high IL-6 levels.
Female sex, being married and having a higher socioeconomic
status were protective.
Currently, there is no standard of care for frailty. Evidence
supporting interventions and strategies to reverse or minimize
frailty varies across the studies; however a high level of evidence
is currently lacking. Interventions for the frailty syndrome
should aim to prevent, delay, reverse or reduce the severity of
frailty and prevent or minimize adverse health outcomes in those
whose frailty is not reversible.
Among the prognostic factors involved in frailty, muscle
strength is one which could be improved with training. In fact,
exercise is the intervention that has shown to result in some
benefit in frailty (20, 169). Exercise has physiologic impacts on
many systems, particularly musculoskeletal, endocrine and
immune systems (9). However, the evidence of achieving good
outcome with exercise is low or very low. Moreover, the optimal
program for physical activity is not known, with studies showing
differences in frequency, intensity, type and duration of
exercise (170).
Another aspect of frailty susceptible to intervention is
nutrition. The correction of nutritional deficiencies, including
micronutrients, improves physical performance but not body
weight; in a meta-analysis the evidence was reported as of
moderate-level certainty, but the study had several biases (171).
A pharmacological approach has been evaluated in a few
studies. As a decline in sex hormones occurs with aging (172)
and low levels are associated with frailty (87), while
supplementation improves performance of organs involved in
frailty as the muscle and the bone (173–175), hormone
replacement therapy with testosterone (in men) or estrogens
(in postmenopausal women) has been evaluated. It obtained
some effect on frailty (176), particularly on muscle strength, but
treatment was burdened with significant systemic side effects,
mainly cardiovascular for testosterone (177), oncogenic for
estrogen supplementation (178).
Vitamin D has a favorable pharmacological and safety profile,
but its clinical utility in frailty has to be better investigated (9).
The use of statins, known to have anti-inflammatory effects
(179), had no association with reduction of incidence of
frailty (180).
An integrated intervention was implemented in Japan, where
people were screened for frailty in primary care. Subjects
identified as pre-frail or frail were referred to a group
community program involving physical activity, nutrition, and
social participation, with substantial functional improvements in
the population in a 10-year period (181).Frontiers in Immunology | www.frontiersin.org 10DISCUSSION
Rheumatic diseases affect patients at any ages and often lead to
progressive reduction in physical capacity, increased
vulnerability to adverse events and thereby to frailty.
Furthermore, current medical treatments allow a longer
survival, thus possibly increasing the incidence and prevalence
of frailty in these patient populations. Our overview on frailty in
rheumatic diseases underlines how important it is considering
this parameter in patient evaluation. In fact, age was non-linearly
correlated to frail state, and the association between frail status
and unfavorable outcomes persisted after adjustment for age
(140, 141, 143, 150, 158, 164). Moreover, some analyses have
been performed in young populations, as it was in a RA cohort
(141) and in SLE patients (150) and frailty was associated with
high disease activity, implying a key role of inflammation.
Accordingly, immunosuppressive therapy could play a major
role in preventing frailty. On the other hand, in AAV it was
shown that patients with a lower vs higher baseline frailty score
had no differences in time to remission or time to relapse, but in
the frailer group a greater proportion of patients had adverse
events, longer in-hospital stay, and mortality was significantly
higher (164). Therefore, while a more aggressive therapy could be
necessary early in the course of rheumatic diseases also to prevent
frailty, in an already frail patient it could jeopardize any expected
advantages and a more conservative management might be
preferable. Both rheumatic diseases and frailty can influence
each other and their severity may vary over time. Therefore, as
the disease activity in rheumatic patients is evaluated regularly and
therapy modified accordingly, frailty should also be assessed
periodically. The introduction in rheumatology of a frailty score
would be a valuable tool to better understand the patient overall
health status and to perform a proper prognostic assessment. The
challenge is to develop a standardized frailty definition and
screening tool, in order to allow an homogeneous assessment
and risk stratification for each disease. A disease-specific scale of
frailty should be defined for each rheumatic condition and would
likely be a proper way to address the issue. In fact, it would include
different or additional factors compared to Fried’s criteria, that
would better predict predisposition to poor outcomes. For
example, a systemic sclerosis-specific scale might include cardio-
pulmonary evaluation, while in rheumatoid arthritis joint-related
problems should be considered. Moreover, the assessment of
disease-related complications is routinely performed during
clinical evaluation, while additional tests are needed for Fried’s
criteria, and this can limit the feasibility in clinical settings. Pilot
studies are reported in this review, but further analyses on larger
casuistries are needed to validate the FI proposed or to identify
other scales. The introduction of frailty scales for rheumatic
diseases may allow a more complete evaluation of the patient in
the clinical setting. In addition, frailty should be evaluated in
clinical trials. Evidence for treatment and current management
recommendations are based on clinical trials, but frail subjects
may not comply with the numerous study requirements or, if
enrolled, they may have an increased dropout rate due to adverse
events. Considering frailty in clinical trials is particularlyOctober 2020 | Volume 11 | Article 576134
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within the same rheumatic disease, but an effort must be made in
this direction. In observational and, most importantly, in
prospective and interventional trials on drugs, frailty have to be
defined and investigated. Moreover, in the analysis of outcomes,
the importance of diagnosing frailty and the impact of potential
interventions to decrease risks have to be evaluated. Patients
stratification according to frailty state could allow a better
management, considering not only the specific disease, but
taking into account also the patient’s global health. The risk-
benefit ratio of glucocorticoids and different immunosuppressive
drugs should be investigated in-depth in frail patients affected by
rheumatic diseases, as they can be more vulnerable to adverse
effects, and a deeper insight of the consequences of treatment on
frailty could help clinical decisions. Furthermore, it would allow to
establish personalized programs to prevent frailty, or reverse or
reduce its severity and to manage the associated complications,
with an enhancement of physical, psycho-social and nutritional
support. Finally, assessment of frailty should be included in real-
life studies, for a better estimate of the impact of proposed
medical treatments.Frontiers in Immunology | www.frontiersin.org 11In conclusion, frailty is an emerging concept in rheumatology
and should be implemented with the definition of disease-
specific scales. In addition, clinical trials should be performed
to study the impact of frailty on different rheumatic diseases,
and, on the other hand, of rheumatic diseases and
immunosuppressive drugs on frailty and related adverse
events. As more treatment options are now available for
rheumatic diseases, the need for tailored therapy has become
increasingly relevant. Further research on frailty could allow to
identify the best treatment approach for each patient, aiming at
minimizing drug-related adverse effects while optimizing
effectiveness and patient outcomes.AUTHOR CONTRIBUTIONS
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